



**DIAGNOSTIC AUTOMATION, INC.**

23961 Craftsman Road, Suite E/F, Calabasas, CA 91302

Tel: (818) 591-3030 Fax: (818) 591-8383

[onestep@rapidtest.com](mailto:onestep@rapidtest.com)

[technicalsupport@rapidtest.com](mailto:technicalsupport@rapidtest.com)

[www.rapidtest.com](http://www.rapidtest.com)

IVD



See external label



2°C-8°C



Σ=96 tests

REF

Cat # 1412Z

# Varicella IgG

Cat # 1412Z

## INTENDED USE

The Diagnostic Automation Varicella-Zoster Virus (VZV) IgG Enzyme-linked Immunosorbent Assay (ELISA) is intended for the detection and quantitative determination of IgG antibody to VZV in human sera. Individual serum specimens may be used for the determination of immune status. Paired sera, acute and convalescent, may be used to demonstrate seroconversion or a significant rise in antibody level, as an aid in the diagnosis of primary infection or reactivation with VZV. **For *in vitro* diagnostic use. High complexity test.**

## Introduction

Varicella, more commonly known as chickenpox, and herpes zoster are known clinical manifestations of infection with varicella-zoster virus (VZV) (1,2,3,4).

Chicken pox, the clinical syndrome usually produced as a result of the primary infection with VZV, is a highly contagious disease characterized by widely spread vesicular eruptions and fever. The disease is endemic in the U.S. and most commonly affects children from five to eight years of age, although adults and younger children, including infants, may develop chickenpox. Every two to five years, usually in the winter or spring, the number of cases increases to epidemic levels. VZV infection during early pregnancy has been implicated in congenital anomalies in rare cases. When infection occurs at term, life-threatening infections can occur in the neonate (1,3,4,5,6,7).

Herpes zoster is mainly a disease of adults, with most cases appearing in patients fifty years or older. Evidence suggests that this manifestation of VZV infections results from a reactivation of virus which has remained latent in the sensory spinal ganglia after the primary infection rather than a reintroduction of the virus into the host (8). Fever and painful localized vesicular eruptions of the skin along the distribution of

the involved nerves are the most common clinical symptoms of the condition. Zoster lesions can be mistaken for the similar lesions produced by herpes simplex virus in which recurrences are common (1,2,3). However, recurrences of herpes zoster are extremely rare.

Determination of the immune status of high risk individuals who are exposed to VZV, the screening for potential donors of Varicella-zoster immunoglobulin, and the diagnosis of VZV infected individuals (both pre- and postnatal) is usually accomplished by serological testing. However, some serological studies suggest that reinfection or reactivation of VZV may occur in the absence of clinical symptoms (8).

The various methods of serodiagnostic tests for the detection of VZV antibodies in a patient's serum include indirect immunofluorescence, neutralization, complement fixation and fluorescent antibody to membrane antigen (FAMA) (9,10,11,12). FAMA is generally considered the most sensitive and specific of the methods, yet requires the use of cell culture which is cumbersome to perform (13). Clinical and correlation studies performed by Shehab and Brunell indicate that the ELISA methodology may be as sensitive and perhaps more specific than the FAMA assay (14). The sensitivity, specificity, and reproducibility of enzyme-linked immunoassays is comparable to other serological tests for antibody, such as immunofluorescence, complement fixation, hemagglutination and radioimmunoassays (19,20,21).

The DAI tech Varicella-Zoster Virus IgG ELISA kit provides all the necessary reagents for the rapid quantitative determination of VZV IgG antibody in human sera.

### ***Principle of the Assay***

Enzyme-Linked Immunosorbent Assays (ELISA) rely on the ability of biological materials (i.e., antigens) to adsorb to plastic surfaces such as polystyrene (solid phase). When antigens bound to the solid phase are brought into contact with a patient's serum, antigen specific antibody, if present, will bind to the antigen on the solid phase forming antigen- antibody complexes. Excess antibody is removed by washing. This is followed by the addition of goat antihuman IgG conjugated with horseradish peroxidase which then binds to the antibody-antigen complexes. The excess conjugate is removed by washing, followed by the addition of Chromogen/Substrate, tetramethylbenzidine (TMB). If specific antibody to the antigen is present in the patient's serum, a blue color develops. When the enzymatic reaction is stopped with 1N H<sub>2</sub>SO<sub>4</sub>, the contents of the wells turn yellow. The color, which is indicative of the concentration of antibody in the serum, can be read on a suitable spectrophotometer or ELISA microwell plate reader (18,19,20,21).

### **Kit Presentation**

#### ***Materials Supplied***

Each kit contains the following components in sufficient quantities to perform the number of tests indicated on the package label.

1. Varicella-zoster virus antigen (inactivated) coated microassay plate: 096 wells, configured in twelve 1x8 strips, stored in a foil pouch with desiccant. (96T: one plate; 480T: five plates)
2. Serum Diluent Type I: Ready for use. Contains proclin (0.1%) as a preservative. (96T: one bottle,30 mL, 480T: two bottles, 60 mL each)
3. Calibrator: Human serum or defibrinated plasma. Sodium azide (<0.1%) and pen/strep (0.01%) added as preservatives, with kit specific factor printed on vial label. The Calibrator is used to calibrate the assay to account for day-to-day fluctuations in temperature and other testing conditions.

- (96T: one vial, 0.4 mL; 480T: one vial, 0.8 mL) \*
4. Positive Control: Human serum or defibrinated plasma. Sodium azide (<0.1%) and pen/strep (0.01%) added as preservatives, with established range printed on vial label. The Positive Control is utilized to control the positive range of the assay.  
(96T: one vial, 0.4 mL; 480T: one vial, 0.8 mL) \*
  5. Negative Control: Human serum or defibrinated plasma. Sodium azide (<0.1%) and pen/strep (0.01%) added as preservatives, with established range printed on vial label. The Negative Control is utilized to control the negative range of the assay.  
(96T: one vial, 0.4 mL; 480T: one vial, 0.8 mL) \*
  6. Horseradish-peroxidase (HRP) Conjugate: Ready to use. Goat antihuman IgG, containing proclin (0.1%) and gentamicin as preservatives.  
(96T: one bottle, 16 mL; 480T: five bottles, 16 mL each)
  7. Chromogen/Substrate Solution Type I: Tetramethylbenzidine (TMB), ready to use. The reagent should remain closed when not in use. If allowed to evaporate, a precipitate may form in the reagent wells.  
(96T: one bottle, 15 mL; 480T: five bottles, 15 mL each)
  8. Wash Buffer Type I (20X concentrate): Dilute 1 part concentrate + 19 parts deionized or distilled water. Contains TBS, Tween-20 and proclin (0.1%) as a preservative.  
(96T: one bottle, 60 mL; 480T: one bottle, 250 mL)
  9. Stop Solution: Ready to use, contains a 1N H<sub>2</sub>SO<sub>4</sub> solution.  
(96T: one bottle, 15 mL; 480T: five bottles, 15 mL each)
- \*Note: serum vials may contain excess volume.**

**The following components are not kit lot # dependent and may be used interchangeably within the DAI ELISA IgG assays: Serum Diluent Type I, Chromogen/Substrate Solution Type I, Wash Buffer Type I, and Stop Solution. Please check that the appropriate DAI Reagent Type (Type I, Type II, etc.) is used for the assay.**

#### ***Additional Requirements***

1. Wash bottle, automated or semi-automated microwell plate washing system.
2. Micropipettes, including multichannel, capable of accurately delivering 10-200 µL volumes (less than 3% CV).
3. One liter graduated cylinder.
4. Paper towels.
5. Test tube for serum dilution.
6. Reagent reservoirs for multichannel pipettes.
7. Pipette tips.
8. Distilled or deionized water (dH<sub>2</sub>O), CAP (College of American Pathology) Type 1 or equivalent (39, 40).
9. Timer capable of measuring to an accuracy of +/- 1 second (0 – 60 minutes).
10. Disposal basins and 0.5% sodium hypochlorite (50 mL bleach in 950 mL dH<sub>2</sub>O).
11. Single or dual wavelength microplate reader with 450 nm filter. If dual wavelength is used, set the reference filter to 600-650 nm. Read the Operator's Manual or contact the instrument manufacturer to establish linearity performance specifications of the reader.

**Note:** Use only clean, dry glassware.

## Storage and Stability

1. Store unopened kit between 2° and 8° C. The test kit may be used throughout the expiration date of the kit. Refer to the package label for the expiration date.
2. Unopened microassay plates must be stored between 2° and 8° C. Unused strips must be immediately resealed in a sealable bag with desiccant and returned to storage between 2° and 8° C.
3. Store HRP Conjugate between 2° and 8° C.
4. Store the Calibrator, Positive Control, and Negative Control between 2° and 8° C.
5. Store Serum Diluent Type I and 20X Wash Buffer Type I between 2° and 8° C.
6. Store the Chromogen/Substrate Solution Type I between 2° and 8°C. The reagent should remain closed when not in use. If allowed to evaporate, a precipitate may form in the reagent wells.
7. Store 1X (diluted) Wash Buffer Type I at room temperature (21° to 25° C) for up to 5 days, or up to one week between 2° and 8° C.

**Note:** If constant storage temperature is maintained, reagents and substrate will be stable for the dating period of the kit. Refer to package label for expiration date. Precautions were taken in the manufacture of this product to protect the reagents from contamination and bacteriostatic agents have been added to the liquid reagents. Care should be exercised to protect the reagents in this kit from contamination.

## Precautions

1. For *in vitro* diagnostic use.
2. The human serum components used in the preparation of the Controls and Calibrator in this kit have been tested by an FDA approved method for the presence of antibodies to human immunodeficiency virus 1 & 2 (HIV 1&2), hepatitis C (HCV) as well as hepatitis B surface antigen and found negative. Because no test method can offer complete assurance that HIV, HCV, hepatitis B virus, or other infectious agents are absent, specimens and human-based reagents should be handled as if capable of transmitting infectious agents.
3. The Centers for Disease Control & Prevention and the National Institutes of Health recommend that potentially infectious agents be handled at the Biosafety Level 2 (36).
4. The components in this kit have been quality control tested as a Master Lot unit. Do not mix components from different lot numbers except Chromogen/Substrate Solution Type I, Stop Solution, Wash Buffer Type I, and Serum Diluent Type I. Do not mix with components from other manufacturers.
5. Do not use reagents beyond the stated expiration date marked on the package label.
6. All reagents must be at room temperature (21° to 25° C) before running assay. Remove only the volume of reagents that is needed. **Do not pour reagents back into vials as reagent contamination may occur.**
7. Before opening Control and Calibrator vials, tap firmly on the benchtop to ensure that all liquid is at the bottom of the vial.
8. Use only distilled or deionized water and clean glassware.
9. Do not let wells dry during assay; add reagents immediately after completing wash steps.
10. Avoid cross-contamination of reagents. Wash hands before and after handling reagents. **Cross-contamination of reagents and/or samples could cause false results.**
11. If washing steps are performed manually, wells are to be washed three times. Up to five wash cycles may be necessary if a washing manifold or automated equipment is used.
12. **Sodium azide inhibits Conjugate activity. Clean pipette tips must be used for the Conjugate addition so that sodium azide is not carried over from other reagents.**

13. It has been reported that sodium azide may react with lead and copper in plumbing to form explosive compounds. When disposing, flush drains with water to minimize build-up of metal azide compounds.
14. Never pipette by mouth or allow reagents or patient sample to come into contact with skin. Reagents containing proclin, sodium azide, and TMB may be irritating. Avoid contact with skin and eyes. In case of contact, flush with plenty of water.
15. If a sodium hypochlorite (bleach) solution is being used as a disinfectant, do not expose to work area during actual test procedure because of potential interference with enzyme activity.
16. Avoid contact of Stop Solution (1N sulfuric acid) with skin or eyes. If contact occurs, immediately flush area with water.
17. **Caution:** Liquid waste at acid pH must be neutralized prior to adding sodium hypochlorite (bleach) solution to avoid formation of poisonous gas. Recommend disposing of reacted, stopped plates in biohazard bags. See Precaution 3.
18. The concentrations of anti-VZV in a given specimen determined with assays from different manufacturers can vary due to differences in assay methods and reagent specificity.

### Specimen Collection and Storage

1. Handle all blood and serum as if capable of transmitting infectious agents.
2. Optimal performance of the DAI ELISA kit depends upon the use of fresh serum samples (clear, non-hemolyzed, non-lipemic, nonicteric). A minimum volume of 50  $\mu$ L is recommended, in case repeat testing is required. Specimens should be collected aseptically by venipuncture (37). Early separation from the clot prevents hemolysis of serum.
3. Store serum between 2° and 8° C if testing will take place within two days. If specimens are to be kept for longer periods, store at -20° C or colder. Do not use a frost-free freezer because it may allow the specimens to go through freeze-thaw cycles and degrade antibody. Samples that are improperly stored or are subjected to multiple freeze/thaw cycles may yield erroneous results.
4. If paired sera are to be collected, acute samples should be collected as soon as possible after the onset of symptoms. The second sample should be collected 14 to 21 days after the acute specimen was collected. Both samples must be run in duplicate on the same plate to test for a significant rise. If the first specimen is obtained late during the course of the infection, a significant rise may not be detectable.
5. The NCCLS provides recommendations for storing blood specimens (Approved Standard - Procedures for the Handling and Processing of Blood Specimens, H18-A. 1990) (37).

### Methods for Use

#### ***Preparation for the Assay***

1. All reagents must be removed from refrigeration and allowed to come to room temperature before use (21° to 25° C). Return all reagents to refrigerator promptly after use.
2. All samples and controls should be vortexed before use.
3. Dilute 60 mL of the 20X Wash Buffer Type I to 1.2 L with distilled and/or deionized H<sub>2</sub>O. Mix well.

#### ***Assay Procedure***

**Note: To evaluate paired sera, both serum samples must be tested in duplicate and run in the same plate. It is recommended that the serum pairs be run in adjacent wells.**

1. Place the desired number of strips into a microwell frame. Allow four (4) Control/Calibrator determinations (one Negative Control, two Calibrators and one Positive Control) per run. A reagent

blank (RB) should be run on each assay. Check software and reader requirements for the correct Control/Calibrator configuration. Return unused strips to the sealable bag with desiccant, seal and immediately refrigerate.

Example Configuration:

Plate Location	Sample Description	Plate Location	Sample Description
1A	RB	2A	Patient #4
1B	NC	2B	Patient #5
1C	Cal	2C	Patient #6
1D	Cal	2D	Patient #7
1E	PC	2E	Patient #8 (Acute 1)
1F	Patient # 1	2F	Patient #8 (Acute 2)
1G	Patient # 2	2G	Patient #8 (Convalescent 1)
1H	Patient # 3	2H	Patient #8 (Convalescent 2)

RB = Reagent Blank - Well without serum addition run with all reagents. Utilized to blank reader.

NC = Negative Control

Cal = Calibrator

PC = Positive Control

- Dilute test sera, Calibrator and Control sera 1:21 (e.g., 10 µL + 200 µL) in Serum Diluent. Mix well. (For manual dilutions it is suggested to dispense the Serum Diluent into the test tube first and then add the patient serum.)
- To individual wells, add 100 µL of the appropriate diluted Calibrator, Controls and patient sera. Add 100 µL of Serum Diluent to reagent blank well. Check software and reader requirements for the correct reagent blank well configuration.
- Incubate each well at room temperature (21° to 25° C) for **25 minutes +/- 5 minutes**.
- Aspirate or shake out liquid from all wells. If using semi-automated or automated washing equipment add 250-300 µL of diluted Wash Buffer to each well. Aspirate or shake out and turn plate upside down and blot on paper toweling to remove all liquid. Repeat the wash procedure two times (for a total of three (3) washes) for manual or semi-automated equipment or four times (for a total of five (5) washes) for automated equipment. After the final wash, blot the plate on paper toweling to remove all liquid from the wells.

**\*\*IMPORTANT NOTE:** Regarding steps 5 and 8 - Insufficient or excessive washing will result in assay variation and will affect validity of results. Therefore, for best results the use of semi-automated or automated equipment set to deliver a volume to completely fill each well (250-300 µL) is recommended. A total of up to five (5) washes may be necessary with automated equipment. **Complete removal of the Wash Buffer after the last wash is critical for the accurate performance of the test. Also, visually ensure that no bubbles are remaining in the wells.**

- Add 100 µL Conjugate to each well, including reagent blank well. Avoid bubbles upon addition as they may yield erroneous results.
- Incubate each well at room temperature (21° to 25° C) for **25 minutes +/- 5 minutes**.
- Repeat wash as described in Step 5.
- Add 100 µL Chromogen/Substrate Solution (TMB) to each well, including the reagent blank well, maintaining a constant rate of addition across the plate.
- Incubate each well at room temperature (21° to 25° C) for **10-15 minutes**.
- Stop reaction by addition of 100 µL of Stop Solution (1N H<sub>2</sub>SO<sub>4</sub>) following the same order of Chromogen/Substrate addition, including the reagent blank well. Tap the plate gently along the

outsides, to mix contents of the wells. The plate may be held up to 1 hour after addition of the Stop Solution before reading.

12. The developed color should be read on an ELISA plate reader equipped with a 450 nm filter. If dual wavelength is used, set the reference filter to 600-650 nm. The instrument should be blanked on air. The reagent blank must be less than 0.150 Absorbance at 450 nm. If the reagent blank is > 0.150 the run must be repeated. Blank the reader on the reagent blank well and then continue to read the entire plate. Dispose of used plates after readings have been obtained.

## Quality Control

For the assay to be considered valid the following conditions must be met:

1. Calibrator and Controls must be run with each test run.
2. Reagent blank (when read against air blank) must be < 0.150 Absorbance (A) at 450 nm.
3. Negative Control must be < 0.250 A at 450 nm (when read against reagent blank).
4. Each Calibrator must be > 0.250 A at 450 nm (when read against reagent blank).
5. Positive Control must be > 0.500 A at 450 nm (when read against reagent blank).
6. The ISR (Immune Status Ratio) Values for the Positive and Negative Control should be in their respective ranges printed on the vial labels. If the Control values are not within their respective ranges, the test should be considered invalid and should be repeated.
7. Additional Controls may be tested according to guidelines, or requirements of local, state, and/or federal regulations or accrediting organizations.
8. Refer to NCCLS C24-A for guidance on appropriate QC practices (38).
9. If above criteria are not met upon repeat testing, contact DAI Technical Services.

## Interpretation

### **Calculations**

1. Mean Calibrator O.D. (Optical Density) - Calculate the mean O.D. value from the two Calibrator determinations.
2. Correction Factor - To account for day-to-day fluctuations in assay activity due to room temperature and timing, a Correction Factor is determined by DAI for each lot of kits. The Correction Factor is printed on the Calibrator vial.
3. Cutoff Calibrator Value - The Cutoff Calibrator Value for each assay is determined by multiplying the Correction Factor by the mean Calibrator O.D. determined in Step 1.
4. ISR Value - Calculate an Immune Status Ratio (ISR) for each specimen by dividing the specimen O.D. Value by the Cutoff Calibrator Value determined in Step 3.

Example:

O.D's obtained for Calibrator = 0.38, 0.42  
Mean O.D. for Calibrator = 0.40  
Correction factor = 0.50  
Cutoff Calibrator Value =  $0.50 \times 0.40 = 0.20$   
O.D. obtained for patient sera = 0.60  
ISR Value =  $0.60/0.20 = 3.00$

### **Analysis**

1. The patients' ISR (Immune Status Ratio) values are interpreted as follows:

ISR	Results	Interpretation
$\leq 0.90$	Negative	No detectable antibody to Varicella-zoster virus by the ELISA test. Such individuals are presumed to be uninfected with rubella and to be susceptible to primary infection.
0.91-1.09	Equivocal	Samples should be retested. See Number (3) below.
$\geq 1.10$	Positive	Indicates presence of detectable IgG antibody to Varicella zoster virus by the ELISA test. Indicative of current or previous infection.

2. Samples that remain equivocal after repeat testing should be retested on an alternate method, e.g., immunofluorescence assay (IFA). If results remain equivocal upon further testing, an additional sample should be taken. (See Limitation No. 4).
3. In the evaluation of paired sera, if the acute specimen is negative and the convalescent specimen is positive, a seroconversion has taken place. This indicates a significant change in antibody level and the patient is undergoing a primary infection.
4. To evaluate paired sera for a significant change in antibody level or seroconversion, both samples must be tested in duplicate in the same assay. The mean ISR of both samples (acute and convalescent) must be greater than 1.00 to evaluate the paired sera for significant rise in antibody level.
5. Additional Quality Control for Paired Sera: (See NOTE under Assay Procedure). As a check for acceptable reproducibility of both the acute sera (tested in duplicate) and the convalescent sera (tested in duplicate), the following criteria must be met for valid results:

$$\frac{\text{Acute 1 ISR}}{\text{Acute 2 ISR}} = 0.8 \text{ to } 1.2 \quad \frac{\text{Convalescent 1 ISR}}{\text{Convalescent 2 ISR}} = 0.8 \text{ to } 1.2$$

6. Compare the ISR of the pairs by calculating as follows:

$$\frac{\text{Mean ISR (second sample)} - \text{Mean ISR (first sample)}}{\text{Mean ISR (first sample)}} \times 100 = \% \text{ RISE IN ISR LEVEL}$$



%RISE IN ISR	INTERPRETATION
<p data-bbox="391 212 509 239">&lt; 30.0%</p> <p data-bbox="391 247 509 275">&gt; 30.0%</p>	<p data-bbox="813 212 1477 386">No significant change in antibody level. No evidence of recent infection. If active disease is still suspected, a third sample should be collected and tested in the same assay as the first sample to look for a significant rise in antibody level.</p> <p data-bbox="813 428 1477 638">Statistically significant change in antibody level detected. This identifies those persons who are presumed to be experiencing recent or current episodes of rubella infection (reactivation, reinfection or a primary infection where the acute specimen was obtained too late to demonstrate seroconversion).</p>

**Note:** When evaluating paired sera, it should be determined if samples with high absorbance values are within linearity specifications of the spectrophotometer. Read the Operator's Manual or contact the instrument's manufacturer to obtain the established linearity specifications of your spectrophotometer.

### Limitations of Use

1. The user of this kit is advised to carefully read and understand the package insert. Strict adherence to the protocol is necessary to obtain reliable test results. In particular, correct sample and reagent pipetting, along with careful washing and timing of the incubation steps and control of incubation temperature are essential for accurate results.
2. This kit is designed to measure IgG antibody in patient samples. Positive results in neonates must be interpreted with caution, since maternal IgG is transferred passively from the mother to the fetus before birth. IgM assays are generally more useful indicators of infection in children below the age of six months.
3. Samples collected very early in the course of an infection (within 5 days after onset of rash) may not have detectable levels of VZV IgG (24). In such cases, it is recommended that an IgM assay be performed, or a second serum sample be obtained 14 to 21 days later to be tested in parallel with the original sample to determine seroconversion, which is indicative of a primary infection (8).
4. Samples that remain equivocal after repeat testing should be retested on an alternate method, e. g. immunofluorescence assay (IFA). If results remain equivocal upon further testing, an additional sample should be taken.
5. Following varicella infection, immunity to exogenous reinfection is lifelong, so that second attacks of the disease are virtually unknown. However, recurrence of the virus may occur in the form of zoster (25), and results of certain serological studies (26,27) suggest that reinfection or reactivation of Varicella-zoster virus (VZV) may occur in the absence of clinical symptoms (8).
6. The results of ELISA performed on serum from patients with immunosuppression or recent blood transfusion must be interpreted with caution.
7. The results of a single specimen antibody determination should not be used to aid in the diagnosis of recent infection. Paired samples (acute and convalescent) should be collected and tested concurrently to look for seroconversion or a significant rise in antibody level.
8. The values obtained from this assay are intended to be an aid to diagnosis only. Each physician must interpret the results in light of the patient's history, physical findings and other diagnostic procedures.

9. A significant rise in antibody level should be used to confirm a clinical diagnosis of atypical varicella or zoster infection only if a patient is tested concurrently for herpes simplex virus (HSV) and does not demonstrate a concurrent significant rise in antibody to herpes simplex. A high proportion (up to one-third) of individuals with primary HSV infections who have experienced prior VZV infection show a heterotypic antibody response to the VZV antigen, making a differential diagnosis between VZV and HSV infection difficult in the absence of clear-cut clinical findings (8,28,29,30,31). A definite diagnosis for patients demonstrating significant rises in antibody for both Varicella-zoster and herpes simplex virus must be made by isolation and/or direct identification of virus from a lesion. The virus causing the infection may not always demonstrate the greater rise in antibody. Frequently, a differential diagnosis can be made on the basis of the fact that antibody to the infecting viral type is absent or at a very low level in the acute-phase specimen, whereas antibody to the viral heterotype is already present (8,33).
10. Lack of a significant rise in antibody does not exclude the possibility of infection with VZV.
11. Although a positive result with this test can be considered evidence of immunity, a person with a negative result may, in fact, also be immune to VZV. The correlation of negative test results determined with this test as they relate to protection from varicella infection has not yet been definitively established. If a definitive determination of immunity is required, all persons with negative results should be retested by a more sensitive assay, e.g., fluorescent antibody to membrane antigen (FAMA) (13).

### Expected Values

Expected values in testing for antibody to VZV may vary depending on patient age and geographic incidence. In temperate climates the peak incidence of infection with VZV occurs in winter and spring, with the highest incidence from 5 to 9 years of age. In the United States 97.5% of healthy adults show serologic evidence of prior infection with VZV. In tropical and subtropical geographic regions infection with VZV typically occurs later in life with a higher proportion of adults found to be seronegative for antibody to VZV (23). IgG antibodies to VZV usually appear in the sera of patients infected with VZV within four days after the onset of symptoms. In one study, 61% of these patients had VZV IgG antibodies within the first six days after onset of exanthem (34). The antibody response in patients with zoster typically shows a rise. Most patients with disseminated zoster have high levels of antibody to VZV immediately after onset of localized lesions (36). The antibody level normally peaks at four to eight weeks and remains high for at least six to eight months. Thereafter, antibody levels may decline two to three-fold but persist at low levels indefinitely. Antibody levels after natural infection may be four to eight-fold higher than after immunization (35).

### Performance Characteristics

#### ***Sensitivity and Specificity***

Two hundred forty-one random samples from a large metropolitan hospital and a Department of Health, both located in the eastern United States, were assayed with the DAI Varicella-Zoster IgG ELISA and a second commercially available ELISA test kit. A commercially available Varicellazoster IgG IFA antibody test was used in all cases of discordant results. The results of this study are as follows in Table I:

DAI ELISA					
		(+)	(-)	Relative Sensitivity	Relative Specificity
IFA and ELISA	+	160	1	99.4%	97.0%
	-	2	64	(160/161)	(64/66)

Equivocals by both ELISA methods were considered indeterminate and these fourteen results (all by DAI) were omitted from the calculations for relative sensitivity and specificity.

### ***Reproducibility***

A study was performed to document typical assay precision with the DAI Varicella-Zoster IgG ELISA product. The mean, SD, and % C.V. were calculated for both Intra and Inter-assay, Inter-lot, and Intra-assay Precision for percent rise in ISR value.

### ***Intra-Assay Precision***

Table II presents the results of four (4) samples individually pipetted in groups of twenty (20) in a single assay.

TABLE 11: Intra-Assay Precision for Varicella-zoster IgG				
	n	Mean ISR	Std Dev	%CV
<b>Serum 1</b>	20	2.91	0.202	7.0%
<b>Serum 2</b>	20	4.99	0.184	3.7%
<b>Serum 3</b>	20	0.84	0.154	18.3%
<b>Serum 4</b>	20	0.53	0.067	12.8%

### ***Inter-Assay Precision***

Table III presents the summary of the Inter-Assay precision data determined by replicate testing of four (4) samples individually pipetted in groups of five (5) on three (3) consecutive days.

TABLE 111: Inter-Assay Precision for Varicella-zoster IgG							
	Day 1	Day 2	Day 3	n	Mean ISR	Std Dev	%CV
<b>Serum 1</b>	2.57	2.41	2.89	3	2.62	0.220	8.4%
<b>Serum 2</b>	4.24	4.01	4.61	3	4.29	0.267	6.3%
<b>Serum 3</b>	0.77	0.84	0.97	3	0.86	0.096	11.2%
<b>Serum 4</b>	0.38	0.52	0.40	3	0.43	0.070	16.3%

### ***Inter-Lot Precision***

Table IV presents a summary of the lot to lot precision data determined by replicate testing of four (4) samples individually pipetted in groups of five (5) using three (3) different lots of reagents.

TABLE IV: Inter-Lot Precision for Varicella-zoster IgG							
	Lot 1	Lot 2	Lot 3	n	Mean ISR	Std Dev	%CV
<b>Serum 1</b>	2.61	2.99	2.95	3	2.85	0.202	7.0%
<b>Serum 2</b>	4.26	5.03	3.96	3	4.42	0.470	10.6%
<b>Serum 3</b>	0.28	0.37	0.49	3	0.38	0.089	23.7%
<b>Serum 4</b>	0.14	0.13	0.14	3	0.14	0.010	7.1%

### ***Intra-Assay Precision for the Percent Rise in ISR Value***

Within run precision of serum pairs was determined by testing duplicates of five sera (numbered 1 to 5), five times and using these values to simulate paired sera evaluations for a significant rise in ISR.

Representative results from five of the seven sera used in this study are presented below in Table V:

<b>Serum Pairing (acute:conv.)</b>	<b>n</b>	<b>Mean % Rise in ISR</b>	<b>SD</b>	<b>%CV</b>	<b>Min.</b>	<b>Max.</b>
2:5	25	11.5%	3.1	27.2	5.6%	18.3%
2:3	25	40.6%	6.3	15.5	31.4%	54.2%
1:4	25	124.0%	6.2	5.0	112.6%	137.3%

### ***Percent Rise in ISR***

A study was conducted to evaluate the percent rise in ISR between simulated paired sera (acute and convalescent) where a significant rise in antibody level would not be expected. Ten sera were diluted for assay twice and then evaluated as paired sera. The results of the study show the calculated percent rise in ISR between the simulated paired sera to be 10.0% or less. A second study was conducted using actual documented clinical acute and convalescent sera. All specimens were tested by the DAI ELISA and an IFA test. Results are presented in Table VI:

<b>Sample*</b>	<b>ISR</b>	<b>%Rise n ISR</b>	<b>IFA Titer</b>	<b>Rise in Titer</b>
1 Acute	1.34	11%	512	2 fold
1 Convalescent	1.49	13%	1024	
2 Acute	1.71		1024	
2 Convalescent	1.93		1024	

### ***Cross-Reactivity Study***

#### ***Method***

A study was performed to determine the cross-reactivity of the DAI Varicella-Zoster IgG ELISA with four samples which tested positive by IFA for HSV-1 IgG (1), HSV-2 IgG (1), EBV IgG (3), CMV IgG (2), Anti- Nuclear Antibody (ANA) (2) and negative for VZV IgG.

#### ***Results***

Negative DAI VZV IgG ELISA test results in all four samples indicate an absence of cross-reactivity of the DAI VZV IgG ELISA with the other members of the Herpesvirus family and with ANA.

### **References**

1. **Weller, T.H.** 1965. Varicella-Herpes Zoster Virus. In: Viral and Rickettsial Infections of Man, 4th edition. F.L. Horstall, Jr. and I.Tamm, eds. pp 915-925.
2. **Young, N.A.** 1976. Chickenpox, Measles and Mumps. In: Infectious Diseases of the Fetus and Newborn Infant. J.S. Remington and J.O. Klein, eds. W.B. Saunders Company, Philadelphia. pp. 521- 583.
3. **Ray, C.G.** 1977. Chickenpox (Varicella) and Herpes Zoster. In: Harrison's Principles of Internal Medicine. G.W. Thorn, et al., ed. Mcgraw-Hill, New York. pp. 1020-1023.
4. **Gershon, A.A.** 1975. Varicella in Mother and Infant. Problems Old and New. In: Infections of the Fetus and the Newborn Infant. S. Krugman and A.A. Gershon, eds. Alan R. Liss, Inc., New York,

- N.Y.
5. **Williamson, A.P.** 1975. The Varicella-Zoster Virus in the Etiology of Severe Congenital Defects. A Survey of Eleven Reported Instances. *Clin. Pediatr.* 14: 533-559.
  6. **Meyers, J.D.** 1974. Congenital Varicella in Term Infants: Risk Reconsidered. *J. Infect. Dis.* 129: 215-217.
  7. **Adelstein, A.M. and J.W. Donovan.** 1972. Malignant Disease in Children Whose Mothers Had Chickenpox, Mumps, or Rubella in Pregnancy. *Brit Med. J.* 4: 629-631.
  8. **Schmidt, N.J.** 1985. Varicella-Zoster Virus. In: *Manual of Clinical Microbiology*, 4th edition. E.H. Lennette, A. Balows, W.J. Hausler, H.J. Shadomy, eds. American Society of Microbiology (ASM), Washington, DC. pp.720-727.
  9. **Brunell, P.A. and Z.M. Shehab.** 1986. Varicella-Zoster. In: *Manual of Clinical Laboratory Immunology*, 3rd edition. N.R. Rose, H. Friedman and J.L. Fahey, eds. ASM, Washington, DC. pp. 502-503.
  10. **Schmidt, N.J., E. H. Lennette, J.D. Woodie and H.H. Ho.** 1985. Immunofluorescent Staining in the Laboratory Diagnosis of Varicella-Zoster Virus Infections. *J. Lab and Clin. Med.* 66: 403-411.
  11. **Lyerla, H.C. and F.T. Forrester.** 1978. Varicella-Zoster Virus. In: *Immunofluorescence Methods in Virology*. U.S. Department of Health, Education, and Welfare. pp. 162-163.
  12. **Weller, T.H. and A.H. Coons.** 1954. Fluorescent Antibody Studies With Agents of Varicella and Herpes Zoster Propagated In Vitro. *Proc. Soc. Exp. Biol. Med.* 87: 789-794.
  13. **Williams, V., A.A. Gershon, and P.A. Brunell.** 1974. Serological Response to Varicella-Zoster Membrane Antigens Measured by Indirect Immunofluorescence. *J. Inf. Dis.* 130: 669-672.
  14. **Shehab, Z. and P.A. Brunell.** 1983. Enzyme-Linked Immunosorbent Assay for Susceptibility to Varicella. *J. Infect. Dis.* 148: 472-476.
  15. **Engvall, E., and P. Perlman.** 1971. Enzyme-Linked Immunosorbent Assay (ELISA) Quantitative Assay of Immunoglobulin G. *Immunochemistry.* 8: 871- 874.
  16. **Engvall, E. and P. Perlman.** 1971. Enzyme-Linked Immunosorbent Assay, ELISA. In: *Protides of the Biological Fluids*, H. Peeters, ed. Proceedings of the Nineteenth Colloquium, Brugge Oxford, Pergamon Press. pp. 553-556.
  17. **Engvall, E., K. and P. Perlmann.** 1971. Enzyme-Linked Immunosorbent Assay. II. Quantitative Assay of Protein Antigen, Immunoglobulin-G, By Means of Enzyme- Labelled Antigen and Antibody- Coated tubes. *Biochem. Biophys. Acta.* 251: 427-434.
  18. **Van Weeman, B. K. and A.H.W.M. Schuurs.** 1971. Immunoassay Using Antigen-Enzyme Conjugates. *FEBS Letter.* 15232-235.
  19. **Bakerman, S.** 1980. Enzyme Immunoassays. *Lab. Mgmt.* August: 21-29.
  20. **Cappel, R., F. De Cuyper, and J. De Braekeleer.** 1978. Rapid Detection of IgG and IgM Antibodies for Cytomegalovirus by the Enzyme-Linked Immunosorbent Assay (ELISA). *Arch. Virol.* 58: 253-258.
  21. **Engvall, E. and P. Perlman.** 1972. Enzyme-Linked Immunosorbent Assay, ELISA. III. Quantitation of Specific Antibodies by Enzyme- Labelled Anti- Immunoglobulins in Antigen-Coated Tubes. *J. Immunol.* 109: 129-135.
  22. **Schauf, V. and M. Tolpin.** 1984. Varicella-Zoster Virus. In: *Textbook of Human Virology*, Belshe, ed. PSG Publishing, Littleton, MA. pp. 829-851.
  23. **Schmidt, N.J., E.H. Lennette, and R.L. Magoffin.** 1969. Immunological Relationship between Herpes Simplex and Varicella- Zoster Viruses Demonstrated by Complement Fixation, Neutralization and Fluorescent Antibody Tests. *J. Gen. Virol.* 4: 321-28.
  24. **Fenner, F., and D.O. White.** 1976. In: *Medical Virology*. Academic Press. p. 308.
  25. **Arvin, A.M., C.M. Koropchak, and A.C. Wittek.** 1983. Immunologic Evidence of Reinfection with Varicella-Zoster Virus. *J. Infect. Dis.* 148: 200-205.
  26. **Gershon, A.A., S.P. Steinberg, W. Borkowsky, D. Lennette, and E. Lennette.** 1982. IgM to Varicella-zoster Virus: Demonstration in Patients with and without Clinical Zoster. *Ped. Infect. Dis.* 1: 164-167.
  27. Gallo, D. and N.J. Schmidt. 1981. Comparison of Anticomplement Immunofluorescence and Fluorescent Antibody-to-Membrane Antigen Tests for Determination of Immunity Status to Varicella-Zoster Virus and for Serodifferentiation of Varicella-Zoster and

Herpes Simplex Virus Infections. J. Clin. Micro. 14: 539-543.

28. **Preissner, C.M., S.P. Steinburg, A.A. Gershon, and T.F. Smith.** 1982. Evaluation of the Anticomplement Immunofluorescence Test for Detection of Antibody to Varicella-Zoster Virus. J. Clin. Micro. 16: 373-376.
29. **Grose, C.F., B.J. Edmond, and P.A. Brunell.** 1977. Complementenhanced neutralizing antibody response to Varicella-Zoster Virus. J. Infect. Dis. 139: 432-437.
30. **Rawls, W.E.** 1979. Herpes Simplex Virus Types 1 and 2 and Herpes Virus Simiae, Chapter 11. In: Diagnostic Procedures for Viral, Rickettsial, and Chlamydial Infections, 5th edition. E.H. Lennette and N.J. Schmidt, eds. American Public Health Association, Inc., Washington, D.C. pp. 337-338.
31. **Cremer, N.E., V.L. Devlin, J.L. Riggs, and S. Hagens.** 1984. Anomalous Antibody Responses in Viral Infection: Specific Stimulation or Polyclonal Activation? J. Clin. Micro. 20: 468-472.
32. **Weller, T.H.** 1979. Varicella and Herpes zoster, Chapter 12. In: Diagnostic Procedures for Viral, Rickettsial, and Chlamydial Infections, 5th edition. E.H. Lennette and N.J. Schmidt, eds. American Public Health Association, Inc., Washington, D.C. pp.375-398.
33. **Arvin, A.M., et al.** 1986. Early Immune Response in Healthy and Immunocompromised Subjects with Primary Varicella-Zoster Virus Infection. J. Infect. Dis. 154: 422-29.
34. **Bogger-Goren, S. et al.** 1982. Antibody Response to Varicella Zoster Virus After Natural or Vaccine-induced Infection. J. Infect. Dis. 146: 260-65.
35. **Brunell, P.A., et al.** 1975. Varicella-Zoster Immunoglobulins During Varicella, Latency, and Zoster. J. Infect. Dis. 132: 49-54.
36. **CDC-NIH Manual.** 1993. Biosafety in Microbiological and Biomedical Laboratories, 3rd edition. U. S. Dept. of Health and Human Services, Public Health Service. pp. 18-24.
37. **National Committee for Clinical Laboratory Standards.** 1990. Procedures for the Collection of Diagnostic Blood Specimens by Venipuncture Approved Standard. NCCLS Publication H18-A.
38. **NCCLS.** 1991. National Committee for Clinical Laboratory Standard. Internal Quality Control Testing: Principles & Definition. NCCLS Publication C24- A.
39. <http://www.cap.org/html/ftpdirectory/checklistftp.html>. 1998. Laboratory General - CAP (College of American Pathology) Checklist (April 1998). pp 28-32.
40. **NCCLS.** 1997. National Committee for Clinical Laboratory Standard. Preparation and Testing of Reagent Water in the Clinical Laboratory. NCCLS Publication C3- A3.

<b>Date Adopted</b>	<b>Reference No.</b>
<b>2004-10-01</b>	<b>DA-Varicella IgG-2008</b>



**DIAGNOSTIC AUTOMATION, INC.**

23961 Craftsman Road, Suite E/F, Calabasas, CA 91302  
 Tel: (818) 591-3030 Fax: (818) 591-8383

**ISO 13485-2003**



Revision Date: 8/21/08

# DAI VZV IgG Summary of Assay Procedure

